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Abstract
Background: Although higher habitual soy intake is associated with lower blood pressure (BP) and stroke incidence,
clinical trials using soy protein or isoflavones on cardiovascular risks yielded inconsistent results. The discrepancies are
hypothesized to be due to the individuals’ intestinal bacterial capacity to metabolite isoflavones daidzein into equol.
Animal and in vitro studies have revealed that equol has stronger estrogen-like and anti-oxidative activity than
isoflavones and possesses natriuretic and vasorelaxant properties which may play an important role in the prevention of
hypertension. However, no clinical trial has examined the effect of equol on BP. We thus propose a 24-week randomized
controlled trial to test the effectiveness of natural S-equol on BP and vascular function among equol non-producers.
Methods/design: This will be a 6-month double-blind, randomized, placebo-controlled trial among 207 non-equol
producing postmenopausal women with prehypertension or early untreated hypertension. Eligible participants
who have completed a 2-week run-in will be randomized to either one of the 3 groups: placebo group, low-equol
group (10 mg/d) and high equol group (20 mg/d). The outcome measures will be conducted at baseline and at
the end of the trial including 24 h ambulatory BP, endothelial function (by ultrasound determined brachial flow
mediated dilation), arterial stiffness (by pulse wave analysis) and other cardiovascular risk factors (lipid profile,
glycemic control and inflammatory biomarkers). Urinary isoflavones will be tested for compliance assessment.
One way analysis of variance will be applied to compare the 6-month changes in ambulatory BP or parameters of
vascular function among the 3 treatment groups.
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Discussion: This study will be performed in community subjects. If the antihypertensive effect of equol is proven,
the provision of natural equol to those high risk adults who are unable to produce equol will have enormous
public health implications for the primary and secondary prevention of hypertension and cardiovascular diseases
on a population basis. The research efforts will also have significant implications for industry in the provision of
suitable soy products for the prevention of hypertension and its related complications.
Trial registration: The trial was registered in ClinicalTrials.gov with identifier of NCT02515682.
Keywords: Equol, Supplementation, Blood pressure, Vascular function, Postmenopausal women
Background
Hypertension is an important public-health challenge
Hypertension is an independent risk factor for cardiovascu-
lar diseases (CVD) and renal impairment [1]. An estimated
1 billion individuals are hypertensive worldwide which is
estimated to increase to 1.56 billion by 2025 [2]. The risk
of CVD will double with each increment of 20/10 mm Hg
(SBP/DBP) from 115/75 mm Hg onwards [3]. A meta-
analysis by He et al. [4] reported that 49.5 % of strokes in a
Chinese population could have been prevented if hyperten-
sion was eliminated. A reduction of systolic BP by only
2 mmHg may result in a 6 % reduction in fatal stroke and
a 4 % reduction in coronary heart disease (CHD) [5]. Thus,
the prevention among the early stage of hypertension will
have enormous public health implications.
Prehypertension (SBP 120–139 mm Hg or DBP 80–
89 mm/Hg) was the strongest predictor of incident hyper-
tension and associated with elevated risk of incident CVD
[3, 6]. Vason et al. [7] observed a 30 % conversion of prehy-
pertension to hypertension over 4 years in the Framingham
cohort study. The conversion is even higher in women than
men and incident hypertension is highest in women aged
above 55 y [8]. Hong Kong 2003/2004 Population Health
Survey [9] reported that prehypertension has the highest
prevalence of 42 % in midlife women aged 50–59y. Pre-
hypertension and its progression to hypertension and
increased risk of CVDs have enormous public health
implications but the treatment of prehypertension is
still debatable [10]. Life-style modification for prehyperten-
sion is recommended [3, 11] but compliance is generally
poor. Treatment by antihypertensive drugs often produces
more or less drug related adverse events, thus the use of
natural remedies has aroused increasing interests.
Vascular function assessment by endothelial function and
arterial stiffness
Hypertension is associated with exaggerated functional
vascular damage such as endothelial dysfunction and in-
creased arterial stiffness [12]. Endothelial dysfunction is
characterized by a reduced capacity of endothelial cells to
suppress processes of inflammation, thrombosis and oxi-
dative stress. Impaired arterial elasticity causes increased
cardiac after-load, coronary arterial blood supply, athero-
genesis and microvascular damage [13]. Vascular dysfunc-
tion is considered as a central pathophysiologic process in
the initiation and progression of hypertension and athero-
sclerosis. Evidence shows lifestyle modification can help
restore endothelial function (EF) and arterial elasticity.
Vascular function can be detected early by several non-
invasive methods such as high-resolution ultrasound and
tonometry system. Brachial flow mediated dilation (FMD)
and pulse wave analysis (PWA) are valuable surrogate
markers of vascular function in hypertensive and other
cardiovascular conditions [14].
Soy, equol and hypertension or cardiovascular health
Soy is a traditional Asian diet. Several large scale cohort
studies [15, 16] have revealed that the higher habitual soy
foods or isoflavones intake is associated with lower BP
and cardiovascular incidence. However, the effective com-
ponents of soy and the underlying mechanisms are still
unclear. Soy protein and isoflavones are the most studied
components in soy with regard to potential health bene-
fits. However, clinical trials using soy protein and/or iso-
flavones have yielded mixed findings on cardiovascular
risks [17, 18]. The discrepancies are hypothesized to be
associated with the individuals’ intestinal capacity to me-
tabolite isoflavones daidzein (one principle isoflavone) into
equol [18]. Setchell et al.[19] proposed that equol could be
the key molecule accounting for the health benefits of soy
or isoflavones. Equol is a metabolite of isoflaovone daizein
by intestinal bacteria. Though the majority of animals pro-
duce equol, only 20-50 % human adults produce equol
following soy/daidzein challenge.
Observational studies have suggested that equol produc-
tion was associated with decreased risk of certain diseases
or conditions such as breast cancer [20], obesity [21],
menopausal symptoms [22], hypertension and vascular
dysfunction [23, 24]. Our recent published data [25] among
648 prehypertensive postmenopausal women also indicated
that equol producers had lower systolic BP (134.8 ± 19.3 vs
138.6 ± 24.8 mmHg, p = 0.028), serum triglyceride (1.29 ±
0.63 vs 1.40 ± 0.78 mmol/l, p = 0.023), total cholesterol
(5.61 ± 0.94 vs 5.77 ± 0.90 mmol/l, p = 0.046) and free fatty
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acid (550.3 ± 200.5 vs 616.6 ± 206.1 μmol/l, p = 0.005) than
equol non-producers.
Clinical trials have reported that the beneficial effect of
soy on cardiovascular health was only present or more
pronounced in equol producers than non-producers on
the improvement of lipids profiles [26–28], blood pressure
[28, 29], vascular function [29, 30] and inflammatory
markers [30], although some did not [31, 32]. However,
most of these findings are from non-prespecified subgroup
analysis of equol-producers, not randomized accordingly.
Equol is currently attracting considerable interest as a
potential pharmaceutical or nutraceutical agent [33]. Equol
occurs as two enantiomeric forms, S-equol and R-equol,
and presents in vivo only as the S-equol [19]. S-equol has a
much higher apparent bioavailability (near half of it circu-
lates in the free form) [33] and slower clearance rate (the
terminal elimination half-life of 7–8 h) than its precursor
daidzein [33]. Equol is superior to all other isoflavones in
its estrogenic property and antioxidant activity [34, 35]. In
vitro cell culture and animal studies [36–39] have demon-
strated that equol possesses natriuretic and vasorelaxant
properties via increasing the transcription of endothelial
nitric oxide synthase (eNOS) and redox-sensitive genes,
enhancing renal blood flow and sodium excretion, which
plays an important role in the attenuation of the develop-
ment of hypertension. To date, several clinical trials have
reported favorable effects of S-equol on reducing bone
resorption [40], alleviating menopausal symptoms [41, 42],
improving glycemic control and reducing LDL-c [43].
However, no randomized controlled trial (RCT) has tested
the effect of natural S-equol on BP and vascular function
among prehypertensive population.
Knowledge gap on equol and hypertension or vascular
function
Although dozens of studies have examined the effect of
soy on BP and cardiovascular health, clinical trials directly
using natural S-equol as supplement are limited. Most of
these studies have relatively short duration and the criteria
for determining equol producing status are not consistent
across all the studies. To date, no RCT has tested the ef-
fect of S-equol on 24 h ambulatory BP and vascular func-
tion among pre-hypertensive subjects. Among previous
studies on the soy and cardiovascular health, BP was al-
ways taken in one or two clinic occasions with few data
on ambulatory BP measurement. It has been well estab-
lished that ambulatory BP (ABP) monitoring offers sub-
stantial advantages over conventional clinic measures due
to a good reproducibility and precision, reducing placebo
effect and excluding white-coat influence.
The study hypotheses and purpose
To address the above limitations, we propose to perform a
24-week randomized controlled trial (RCT) among non-
equol producing post-menopausal women with pre-
hypertension or initial untreated hypertension to verify if
natural S-equol has anti-hypertensive effects or can im-
prove vascular function and other cardiovascular risks
(lipids, glucose, and inflammatory biomarkers). To control
for the influence of equol phenotype, we will limit the par-
ticipants to non-equol producers since self-produced
equol from habitual soy intake in equol producers may
neutralize the health effect of equol supplementation.
Considering a high prevalence of prehypertension in
midlife Hong Kong women [9] and a relatively good
compliance of intervention in this age group in our pre-
vious trial [44], the study will be conducted in post-
menopausal women. We hypothesized that natural S-
equol could decrease BP and improve vascular function
in equol non-producers of postmenopausal women with
untreated prehypertension or early hypertension. There is
a dose–response effect with higher dosage of natural S-
equol producing more prominent effects on these health
outcomes than that of low dose.
Method/design
This study will be a 6-month double-blind, randomized,
placebo-controlled trial with three intervention arms.
Participants
Our recently completed RCT [45] has screened out 292
equol non-producers of postmenopausal women with un-
treated prehypertension or hypertension. Subjects have
been recruited from community or health assessment cen-
ter via advertisements in newspaper or referrals. They
were initially screened using a standardized questionnaire
and their eligibility will be further confirmed at research
centre based on the pre-defined criteria.
Inclusion criteria
Hong Kong Chinese women aged 45–65 y with 2 ~ 8 years
menopausal; mean SBP above 130 mmHg or DBP above
80 mmHg or both based on an average of 6 BP readings
on two different occasions measured by sphygmomanom-
eter. Equol non-producer is defined as 24-hour urinary
log10 S-equol:daidzein ratio less than −1.75 after daidzein
challenge (60 mg daidzein daily for 7 consecutive days)
[46]. Written informed consent will be obtained from all
the participants prior to enrolment. Ethics approval has
been obtained from the Clinical Research Ethics Commit-
tee of the Chinese University of Hong Kong (CREC Ref.
No.: CRE-2013.119-T).
Exclusion criteria
Subjects on anti-hypertensive medication or with average
SBP ≥ 160 or DBP ≥ 100 or both; use of medications
known to affect BP within past 6 months (hormone ther-
apy, hypoglycemic or weight reduction agents); medical
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history or presence of certain chronic diseases (stroke, car-
diac infarction, severe liver and renal disease etc.) that
could affect BP or limit the individual’s ability to partici-
pate in the study; present or history of breast cancer,
endometrial cancer, ovarian cancer, thyroid disorder, ab-
normal uterine bleeding after menopause; on diet for
weight loss, glucose or cholesterol reduction or vegetarian
diet; regular smoker or alcohol consumption more than
30 g/day; known soy allergy.
Sample size planning
Our previous RCT [47] on soy showed a 4.2 mmHg net
reduction (SD of change 10 mmHg) in SBP after 6-month
soy protein and isoflavones supplementation relative to
placebo group among 130 pre- and hypertensive postmen-
opausal women [48]. Assuming a reduction of 5 mmHg of
treatment effect on SBP (main effect), 63 subjects per
group will yield a power of at least 80 % at 5 % level of
significance (for a 2-side t-test). Allowing for 10 % non-
compliance or drop out from the study, 69 subjects per
group and a total 207 subjects (63 × 3 × 110 %) will be re-
cruited. Similar attrition rates (7.8 % and 7.0 %) have been
reported in our previous soy trials [45, 49].
Intervention regimes and supplement preparation
Two hundred seven eligible equol-non-producers of
post-menopausal women who have completed a 2-week
run-in period will be randomized to either one of the 3
groups; placebo group, low-equol group (10 mg/d) and
high equol group (20 mg/d).
The dose of natural S-equol used in the present study
is determined mainly on previous studies. A 10 mg nat-
ural S-equol is reported to be effective for improving
menopausal symptoms [41] and bone turnover [40] with
no observed side effect. A higher dose of 30 mg/d for
12-week [42] or even 160 mg/d for 14-day [50] in previ-
ous pilot studies did not reveal any serious adverse
events except for one woman developing a rash [42].
The safety of S-equol has been confirmed in genotoxi-
city [51], acute and subchronic toxicity [52], and repro-
ductive and development toxicity tests [53].
In order to obtain good blinding effect and improve
supplement solubility in water, 10 g soy flour will be in-
cluded in all 3 groups. Our previous trials have shown
soy product was more acceptable to mid-life women
than milk powder. Starch will be added to supplements
to make 3 groups of packets with similar weight. The
natural S-equol will be purchased from Otsuka Pharma-
ceutical Co. Ltd (Japan). The supplements of 3 groups
will be processed by a local GMP certified pharmaceut-
ical company. Daily dosage will be filled into identical
looking packets. The supplements will be delivered to
subjects every four weeks.
Supplement will be suggested to be mixed with 100 ml
of water, juice, milk or adding to soft foods such as oat-
meal and intake daily before breakfast. Subjects will be
asked to maintain their usual level of physical activity, dis-
continue the use of other dietary and herbal supplements
(i.e., dietary fiber, minerals, Vitamin C and E, fish oils,
flavonoids etc.) known to influence BP, minimize the in-
take of soy foods (≤2 servings per week), refrain from high
salt diet and restrict alcohol intake (≤2 drinks per week).
Run-in exercise
Prior to the study proper, a 2-week run-in exercise with
the use of placebo supplement (20 mg starch + 10 mg
soy flour), will be carried out to familiarize the subjects
with the trial requirements. Subjects who consume
≥90 % of supplements provided and without any side-
effects will be formally enrolled into the study.
Randomization procedures
A block randomization will be used for subject allocation.
207 continuous serial numbers (1–207) will be divided into
23 blocks with a block size 9. In each block, three treat-
ments will be randomly allocated for each serial number
based on the sequence of computer generated random
numbers by SPSS (Release 16, SPSS Inc., Chicago, USA).
The 207 serial numbers will be labeled on the correspond-
ing supplements. Each serial number will correspond to
one of three treatments. The supplements will be assigned
to participants according to the sequence of their visits after
the completion of the run-in period. Three treatments will
then be randomly allocated to the three groups.
Blinding and code breaking procedures
The three identical looking supplements will be labeled
with a serial number by a co-investigator who is not re-
sponsible for subject contact and assessment. Partici-
pants, investigators and laboratory technicians will be
blinded to the treatment assignment until the conclusion
of the trial. The principal investigator will be responsible
for breaking the randomization code after the comple-
tion of data analyses or in emergency situations. Inten-
sive effort will be undertaken to locate a subject who fail
to attend for follow-up interview or examination. Reason




S-equol Starch soy flour
Placebo 0 20 mg 10 g 69 6-month
Low-equol 10 mg 10 mg 10 g 69 6-month
High-equol 20 mg 0 10 g 69 6-month
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Data collection
Twenty-four hours ABP, vascular function, overnight fast-
ing (10–12 h) venous blood samples and 24-hour urine
samples will be measured or collected at baseline and at
24 weeks after treatment. Plasma/serum will be isolated
within 2 h after collection. Specimens will be stored at
−80 °C till analyses. All samples from each subject will be
run in the same assay/batch to avoid inter-assay variabil-
ity. Structured questionnaire interview and anthropomet-
ric measurements will be administered at baseline and at
24 weeks. Habitual dietary intakes will be evaluated by a
validated food frequency questionnaire and habitual phys-
ical activity by Modified Baecke questionnaire validated in
Hong Kong population. Urinary analysis for sodium, po-
tassium, and creatinine will be tested by Hitachi 917 auto-
analyzer, Roche Diagnostics.
Primary outcome measures—24-hour ambulatory BP
All arterial parameters will be measured at baseline and
24 weeks by an experienced research assistant. Partici-
pants will be asked to fast for 8 h and withhold vaso-
active medications, alcohol, and caffeine for 12 h before
the study visit.
24-hour ambulatory BP
Twenty-four hours ABP will be measured with ABP
Monitor (TM2430, A&D Company, Limited, Japan) based
on a standard protocol [54]. Participants will be fitted with
an ABP monitor by a trained investigator, with the cuff
attached to the non-dominant upper arm for the entire
24-hour period. The measurements will be carried out
every 30 min during the daytime (from 06:00 a.m. to
12:00 p.m.) and 60 min during the night (1:00 a.m. to
06:00 a.m.), providing at least 40 valid readings of BP
throughout the 24-hour. Participants will be received ver-
bal and written instructions on the monitors and complete
a diary to record sleep, medication, posture activity and
symptoms. A series of calibration readings will be taken
with a mercury sphygmomanometer (within 5 mm Hg of
the mercury readings). The mean values of SBP and DBP
in all day will be calculated by the device-specific software.
Secondary outcome measures- vascular function
Brachial endothelial function by flow mediated dilation (FMD)
Vascular endothelial function will be assessed with high-
resolution ultrasound (SIMENS, ACUSON S2000) on the
brachial artery during reactive hyperemia by standard
methodology [55]. Ischemia is induced with a suprasystolic
pressure cuff around the upper portion of the arm. After
exactly 5 min of occlusion, reactive hyperemia will ensue
and the peak brachial artery diameter will be measured be-
tween 45 and 75 s. Percentage FMD is defined as the dif-
ference between the maximal brachial artery diameter
during reactive hyperemia and the baseline divided by the
baseline brachial artery diameter.
Arterial stiffness and stenosis by pulse wave analysis (PWA)
PWA will be performed by a dedicated tonometry system
(VP-2000; Omron Healthcare, Inc. Bannockburn, Illinois,
USA), following a standardized procedure [56]. Patients
will be fitted with sphygmomanometer cuffs on both arms
and legs and a carotid artery pressure sensor on the neck.
Pulse wave velocity (PWV) will be determined from re-
corded pressure wave forms over both the brachial-ankle
and the heart-ankle arterial segments, which are derived
from computer generated pulse transit times and mea-
sured distances between the two recording sites. Ankle
brachial index (ABI) is the ratio of SBP of ankle to brachial
reflecting lower-extremity arterial stenosis.
Tertiary outcomes
Biomarkers for endothelial function and inflammation
Serum endothelin-1 (ET-1), soluble vascular cell adhesion
molecule–1 (VCAM-1), soluble intercellular adhesion
molecule–1 (ICAM-1) and E-selectin will be measured by
commercial ELISA kits. Serum C-reactive protein (CRP)
will be measured with a validated high sensitivity immu-
noturbidimetric assay.
Other cardiovascular risk markers
Anthropometric measurements, plasma lipids profile and
fasting glucose will be conducted at baseline and 6-month.
Height, weight, waist and hip circumference, body fat per-
centage will be measured by standardized procedure. Body
mass index (BMI), and waist to hip ratio (WHR) will be
calculated. Serum/plasma glucose, triglyceride, total
cholesterol, HDL and LDL cholesterol will be analyzed
(Hitachi 917 auto-analyzer, Roche Diagnostics).
Assessment of compliance
Compliance will be assessed by counting the returned sup-
plements and estimation of percentage of intake, as well as
urinary excretion of isoflavones at baseline and 24 weeks.
Urinary isoflavones including daidzein and equol will be
determined by high performance liquid chromatography
(HPLC).
Statistical analysis
Relevant parametric and non-parametric tests will be used
for testing the differences in the baseline characteristics
and outcomes of post treatment among the three study
groups. The major approach of analysis will be one way
analysis of variance (ANOVA) to compare the change and
percentage change of outcomes at 24 weeks among the
three groups. Analysis of covariance will also be made to
examine if the results are similar after adjusting for poten-
tial confounders. The primary analysis will be an intention
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to treat (ITT) analysis that included all subjects who are
randomized. A secondary per protocol analysis will be per-
formed including subjects with good compliance (defined
as subjects who consumed ≥ 80 % of provided supplements
or with urinary isoflavones level above predefined values
for valid users). The non-compliant subjects will be de-
scribed and compared to the compliant subjects. Dose-
dependent effects will be evaluated with the Jonckheere’s
trend test. The Bonferroni test will be used for post hoc
multiple comparisons among the three groups. The pri-
mary outcome variables of 24 h ambulatory BP (mean
SBP and mean DBP in all day) will be tested at a signifi-
cance level of 2.5 % in order to maintain an overall 5 %
level. The two important secondary outcomes for as-
sessment of vascular function (%FMD and PWV) will
be tested at a significant level of 1.25 %. Exploratory
analyses will be used to test each of the tertiary out-
comes at the 5 % significance level. Further stratifica-
tion analysis will be conducted to examine if the effects
differed across subgroups such as years since meno-
pause and BMI etc.
Results
The proposed study flow chart is indicated in Fig. 1.
Baseline characteristics of 292 pre-hypertensive post-
menopausal women who were non-equol producers
were listed in Table 1.
Discussion
The results of this RCT will produce direct evidence on
the effectiveness of natural S-equol on BP and vascular
function among equol non-producing Chinese postmeno-
pausal women with pre-hypertension or early untreated
hypertension. To our knowledge, this will be the first RCT
specifically conducted among non-equol producers to test
the effectiveness of S-equol supplementation on BP and
vascular function, and also provide evidence for the opti-
mal dosage of equol. S-equol is natural supplement de-
rived from soy germ by fermentation. The proposed level
of intake has been used in several clinical trials. No severe
adverse effects have been observed in human studies.
This randomized, double-blind, placebo-controlled trial
will be performed in community subjects with prehyper-
tension or early untreated hypertension. If the antihyper-
tensive effect of natural S-equol is proven, the provision of
natural equol to those high risk adults who are unable to
produce equol due to a lack of intestinal equol-producing
bacteria or some other factors, could have enormous pub-
lic health implications for the primary and secondary pre-
vention of hypertension and cardiovascular diseases on a
population basis. These research efforts may provide alter-
native remedy to improve cardiovascular health, and also
have significant implications for industry in the provision
of suitable soy products or supplementation for the preven-
tion of hypertension and its related complications. With
the high prevalence of hypertension in postmenopausal
Fig. 1 Study flow chart of the proposal
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women, this study on the hypotensive effect of equol will
explore an area with important public health implications
both locally and internationally.
Ethics approval
The study ethics was approved by the Ethics committee
of the Chinese University of Hong Kong (CREC Ref.
No.: CRE-2013.119-T)
Abbreviations
ABPM: ambulatory BP monitor; ANOVA: one way analysis of variance;
BMI: body mass index; BP: blood pressure; CHD: coronary heart disease;
CRP: C-reactive protein; CVD: cardiovascular diseases; EF: endothelial function;
ET-1: endothelin-1; FMD: flow mediated dilation; HPLC: high performance
liquid chromatography; ICAM-1: soluble intercellular adhesion molecule–1;
PWA: pulse wave analysis; RCT: randomized controlled trial; VCAM-1: soluble
vascular cell adhesion molecule–1; WHR: waist to hip ratio.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
ZML conceived the study and drafted the study protocol. YMC helped in
biochemical testing. Other co-authors critically reviewed and revised the
research protocol. All authors read and approved the final manuscript.
Acknowledgements
This work is partially supported by Hong Kong Research Grant Committee-
General Research Fund (RGC-GRF465810) for the screening data collection.
Author details
1Division of Family Medicine and Primary Care, The Jockey Club School of
Public Health and Primary Care, the Chinese University of Hong Kong, Hong
Kong, SAR. 2Division of Epidemiology, The Jockey Club School of Public
Health and Primary Care, the Chinese University of Hong Kong, Hong Kong,
SAR. 3Department of Medical Statistics and Epidemiology, School of Public
Health, Sun Yat-sen University, Guangzhou, PR China. 4School of Nursing,
Faculty of Health and Social Science, the Hong Kong Polytechnic University,
Hong Kong, SAR. 5Department of Sport and Health, Guangzhou Sport
University, Guangzhou, PR China. 6Department of Nutrition, School of Public
Health, Sun Yat-sen University, Guangzhou, PR China.
Received: 6 August 2015 Accepted: 23 February 2016
References
1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, Jones Jr
DW, Materson BJ, Oparil S, Wright Jr. JT, et al. The Seventh Report of the Joint
National Committee on Prevention, Detection, Evaluation, and Treatment of
High Blood Pressure: the JNC 7 report. Jama. 2003;289(19):2560–72.
2. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J.
Global burden of hypertension: analysis of worldwide data. Lancet.
2005;365(9455):217–23.
3. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, Jones
Jr DW, Materson BJ, Oparil S, Wright Jr. JT, et al. Seventh report of the Joint
National Committee on Prevention, Detection, Evaluation, and Treatment of
High Blood Pressure. Hypertension. 2003;42(6):1206–52.
4. He J, Klag MJ, Wu Z, Whelton PK. Stroke in the People’s Republic of China. II.
Meta-analysis of hypertension and risk of stroke. Stroke. 1995;26(12):2228–32.
5. Whelton PK, He J, Appel LJ, Cutler JA, Havas S, Kotchen TA, Roccella EJ,
Stout R, Vallbona C, Winston MC et al. Primary prevention of hypertension:
clinical and public health advisory from The National High Blood Pressure
Education Program. Jama. 2002;288(15):1882–8.
6. Gu D, Wildman RP, Wu X, Reynolds K, Huang J, Chen CS, He J. Incidence
and predictors of hypertension over 8 years among Chinese men and
women. J Hypertens. 2007;25(3):517–23.
7. Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency of
progression to hypertension in non-hypertensive participants in the
Framingham Heart Study: a cohort study. Lancet. 2001;358(9294):1682–6.
8. Jimenez-Corona A, Lopez-Ridaura R, Stern MP, Gonzalez-Villalpando C.
Risk of progression to hypertension in a low-income Mexican population with
prehypertension and normal blood pressure. Am J Hypertens.
2007;20(9):929–36.
9. Population Health Survey 2003/2004. Department of Health, Hong Kong.
[http://www.chp.gov.hk/files/pdf/report_on_population_health_survey_
2003_2004_en.pdf]. Accessed July 2015.
10. Mitka M. Drug therapy for prehypertension questioned. Jama. 2006;296(23):
2787–8.
11. Tejada T, Fornoni A, Lenz O, Materson BJ. Nonpharmacologic therapy for
hypertension: does it really work? Curr Cardiol Rep. 2006;8(6):418–24.
Table 1 Baseline characteristics among 292 non-equol
producing postmenopausal women with prehypertension
Non-Equol producers
n 292
Age (y) 57.6 ± 4.6
Menopausal years (y) 8.2 ± 5.3
Age at menarche(y) 13.2 ± 1.8
Ever use of contraceptives (%) 126 (50.6)
Ever use of HRT (%) 38 (15.3)
Dietary intake (from FFQ)
Energy (kcal/d) 2100.7 ± 1018.6
Protein (g/1000 kcal) 55.8 ± 13.2
Total fat (g/1000 kcal) 21.2 ± 6.9
Fiber (g/1000 kcal) 21.0 ± 8.8
Cholesterol (mg/1000 kcal) 146.2 ± 90.1
Isoflavones (mg/1000 kcal) 7.03 ± 7.83
Total PA (MET-min/d) 1445.6 ± 728.2
Occupational PA 586.1 ± 759.5
Housework PA 558.7 ± 459.9
Sports PA 141.0 ± 166.2
Habitual tea drinking (%) 195 (78.6)
Habitual alcohol drinking (%) 18 (7.3)
Habitual coffee drinking (%) 84 (33.9)
Passive smoking (%) 43 (17.4)
Anthropometrics measures, BP and lipids
Body weight (kg) 55.7 ± 9.0
BMI (kg/m2) 23.0 ± 3.2
WHR 0.838 ± 0.050
SBP (mmHg) 135.1 ± 16.6
DBP (mmHg) 83.1 ± 9.6
TG (mmol/L) 1.41 ± 0.79
TC (mmol/L) 5.76 ± 0.90
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